Wall Street brokerages predict that Syneos Health Inc (NASDAQ:SYNH) will report earnings of $0.83 per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Syneos Health’s earnings. The highest EPS estimate is $0.84 and the lowest is $0.82. Syneos Health reported earnings of $0.75 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 10.7%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Syneos Health will report full year earnings of $3.17 per share for the current financial year, with EPS estimates ranging from $3.17 to $3.18. For the next financial year, analysts expect that the firm will post earnings of $3.63 per share, with EPS estimates ranging from $3.54 to $3.68. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Syneos Health.

Syneos Health (NASDAQ:SYNH) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.02. Syneos Health had a return on equity of 9.82% and a net margin of 0.36%. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter in the previous year, the company posted $0.62 earnings per share. The business’s revenue was up 8.8% on a year-over-year basis.

Several analysts have weighed in on SYNH shares. KeyCorp boosted their price objective on Syneos Health from $59.00 to $63.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th. SunTrust Banks boosted their price objective on Syneos Health to $68.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Zacks Investment Research upgraded Syneos Health from a “sell” rating to a “hold” rating in a research report on Friday, May 24th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Syneos Health currently has an average rating of “Buy” and an average price target of $55.75.

SYNH stock traded down $0.83 during midday trading on Thursday, hitting $51.16. The company had a trading volume of 195,278 shares, compared to its average volume of 623,925. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 0.99. Syneos Health has a 52 week low of $36.26 and a 52 week high of $56.34. The stock’s 50 day moving average price is $49.82 and its 200 day moving average price is $48.22. The stock has a market cap of $5.28 billion, a price-to-earnings ratio of 19.53, a PEG ratio of 1.78 and a beta of 1.53.

Several institutional investors have recently made changes to their positions in the stock. Financial Gravity Wealth Inc. purchased a new stake in Syneos Health in the second quarter worth $29,000. AlphaOne Investment Services LLC grew its stake in Syneos Health by 29.0% in the first quarter. AlphaOne Investment Services LLC now owns 1,590 shares of the company’s stock worth $82,000 after purchasing an additional 357 shares during the period. CSat Investment Advisory L.P. purchased a new stake in Syneos Health in the second quarter worth $136,000. Private Capital Group LLC grew its stake in Syneos Health by 75.5% in the first quarter. Private Capital Group LLC now owns 3,201 shares of the company’s stock worth $166,000 after purchasing an additional 1,377 shares during the period. Finally, Starr International Co. Inc. purchased a new stake in Syneos Health in the first quarter worth $167,000.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Recommended Story: What is the definition of a trade war?

Get a free copy of the Zacks research report on Syneos Health (SYNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.